(IN BRIEF) Sanofi has agreed to acquire Provention Bio, a U.S.-based biopharmaceutical company focused on preventing and intercepting immune-mediated diseases, for $2.9 billion. The acquisition includes Provention Bio’s first-in-class therapy for type 1 diabetes, TZIELD, which was approved in the … Read the full press release →
Posted in Business, France, Healthcare, Management, News, Pharma & Biotech, Science
Tagged acquisition, Ashleigh Palmer, France, Immune-Mediated Disease, Olivier Charmeil, Provention Bio, Sanofi, transformative therapy, type 1 diabetes, TZIELD